Quattro Financial Advisors LLC Raises Stock Position in Moderna, Inc. (NASDAQ:MRNA)

Quattro Financial Advisors LLC grew its position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 36.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 84,600 shares of the company's stock after acquiring an additional 22,500 shares during the quarter. Moderna accounts for approximately 0.9% of Quattro Financial Advisors LLC's portfolio, making the stock its 25th largest holding. Quattro Financial Advisors LLC's holdings in Moderna were worth $3,439,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in MRNA. State Street Corp boosted its position in Moderna by 12.1% in the third quarter. State Street Corp now owns 16,847,212 shares of the company's stock worth $1,125,899,000 after purchasing an additional 1,823,276 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Moderna by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company's stock worth $470,670,000 after purchasing an additional 178,115 shares during the period. Wellington Management Group LLP boosted its holdings in shares of Moderna by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company's stock worth $349,166,000 after buying an additional 906,114 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Moderna by 0.5% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company's stock valued at $260,023,000 after buying an additional 19,819 shares during the period. Finally, The Manufacturers Life Insurance Company increased its holdings in Moderna by 6.2% during the third quarter. The Manufacturers Life Insurance Company now owns 3,073,934 shares of the company's stock worth $205,431,000 after buying an additional 178,939 shares during the last quarter. Institutional investors own 75.33% of the company's stock.

Analyst Ratings Changes

MRNA has been the topic of a number of research analyst reports. Hsbc Global Res upgraded shares of Moderna from a "hold" rating to a "strong-buy" rating in a research note on Monday, November 18th. Jefferies Financial Group lowered their price target on shares of Moderna from $65.00 to $55.00 and set a "hold" rating on the stock in a report on Tuesday, October 15th. Argus lowered Moderna from a "buy" rating to a "hold" rating in a report on Wednesday, December 18th. Bank of America reiterated an "underperform" rating and issued a $41.00 target price on shares of Moderna in a research note on Tuesday, December 10th. Finally, Sanford C. Bernstein started coverage on Moderna in a research note on Thursday, October 17th. They set a "market perform" rating and a $55.00 price objective on the stock. Four investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, four have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $67.26.

Moderna Price Performance

Shares of NASDAQ MRNA traded down $0.73 during mid-day trading on Monday, reaching $31.87. 10,887,686 shares of the company were exchanged, compared to its average volume of 12,586,851. Moderna, Inc. has a 52 week low of $31.66 and a 52 week high of $170.47. The company's 50 day moving average price is $40.01 and its 200 day moving average price is $57.38. The stock has a market capitalization of $12.26 billion, a PE ratio of -5.48 and a beta of 1.59. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($1.89) by $1.92. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The firm had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.25 billion. During the same period last year, the firm posted ($1.39) earnings per share. The business's revenue was up 3.8% compared to the same quarter last year. Sell-side analysts forecast that Moderna, Inc. will post -8.95 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the firm's stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the transaction, the insider now owns 19,717 shares in the company, valued at approximately $843,690.43. This trade represents a 6.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last three months, insiders have sold 2,664 shares of company stock valued at $115,210. 15.70% of the stock is currently owned by insiders.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.